Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by several executives on June 9, 2011, at a price of 1,297 pence per share through the Company's Share Reward Plan. The transactions involved both personal contributions (partnership element) and company contributions (matching element). Specific acquisitions included:
- Mr A P Witty, Mr S Dingemans, Mr S M Bicknell, Mr E J Gray, Mr D S Redfern, Ms C Thomas, and Mrs V A Whyte: Acquired 10 shares each under both the partnership and matching elements.
- Mr P C Thomson: Acquired 6 shares under both the partnership and matching elements.
- Dr P J T Vallance: Acquired 9 shares under both the partnership and matching elements.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share transactions described above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,297 pence per Ordinary share on June 9, 2011.
- Confirm the total number of shares acquired by each listed executive under the Share Reward Plan.
- Review the company's broader Share Reward Plan rules to understand the matching contribution structure.